-
Subclinical synovitis impact on the progression of lupus joint disease: A 10-year longitudinal multicenter study Lupus (IF 2.6) Pub Date : 2024-03-16 Carlos A Guillén-Astete, Marcelino Revenga-Martínez, Antonio C Zea-Mendoza, María E Brito-Brito, Pablo Zurita-Prada, Claudia Urrego-Laurín, Lourdes Villalobos-Sánchez, Nuria García-Montes, Mónica Vázquez-Díaz
ObjectiveTo determine the effect of subclinical synovitis on the progression of joint disease in a cohort of patients with systemic lupus erythematosus over a mean follow-up of 10 years.MethodsA longitudinal follow-up of 96 patients diagnosed with lupus was performed. All patients were considered clinically free of joint disease or with minimal joint impairment at baseline and were studied through
-
Global tuberculosis disease and infection in systemic lupus erythematosus patients: A systematic review and meta-analysis Lupus (IF 2.6) Pub Date : 2024-03-16 Guntur Darmawan, Lie Monica Sherine Liman, Suryo Anggoro Kusumo Wibowo, Laniyati Hamijoyo, Lika Apriani, Nur Atik, Bachti Alisjahbana, Edhyana Sahiratmadja
BackgroundTuberculosis (TB) is one of the most common infections among systemic lupus erythematosus (SLE) patients. We aimed to evaluate the global prevalence of TB infection and disease, its type, and medication risk factors in SLE patients.MethodsWe searched PubMed, Science Direct, EBSCO, and Web of Science databases from inception to April 30, 2023, and included studies assessing TB among SLE patients
-
Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications Lupus (IF 2.6) Pub Date : 2024-03-12 Hiroshi Oiwa, Takeshi Suga, Yohei Hosokawa, Kei Araki
ObjectivesIn addition to various immunosuppressive agents, belimumab and anifrolumab became available in Japan. We aimed to investigate glucocorticoid-free clinical remission in a single-centre retrospective cohort in October 2023.MethodsOur cohort included patients with SLE who needed to start or increase glucocorticoids for disease activity and were followed up for more than 1 year. We investigated
-
Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus Lupus (IF 2.6) Pub Date : 2024-03-08 Shun Hashimoto, Masashi Fujita, Tomomi Aizawa, Shojiro Watanabe, Koji Tsugawa, Hiroshi Tanaka
-
Using combination of albumin to fibrinogen ratio and prognostic nutritional index model for predicting disease activity in patients with systemic lupus erythematosus Lupus (IF 2.6) Pub Date : 2024-03-08 Hongshuai Zhao, Zikun Huang, Shiqian Wang, Peng Fu, Biqi Fu, Yang Guo, Junming Li, Qing Luo
Background: Systemic lupus erythematosus (SLE) is chronic autoimmune disease with multiple organ damage and is associated with poor prognosis and high mortality. Identification of universal biomarkers to predict SLE activity is challenging due to the heterogeneity of the disease. This study aimed to identify the indicators that are sensitive and specific to predict activity of SLE.Methods: We retrospectively
-
Comparison of late-onset and non-late-onset systemic lupus erythematosus individuals in a real-world electronic health record cohort Lupus (IF 2.6) Pub Date : 2024-03-08 Ganiat Adeogun, Alex Camai, Ashley Suh, Lee Wheless, April Barnado
Objective: Late-onset systemic lupus erythematosus (LO-SLE) is defined as SLE diagnosed at age 50 years or later. Current studies on LO-SLE are small and have conflicting results.Methods: Using a large, electronic health record (EHR)-based cohort of SLE individuals, we compared demographics, disease characteristics, SLE-specific antibodies, and medication prescribing practices in LO ( n = 123) vs.
-
Childhood adverse experiences and clinical manifestations in women with systemic lupus erythematosus Lupus (IF 2.6) Pub Date : 2024-03-08 Elisa Esteves Rossini, Jonatas Lourival Zanoveli Cunha, Gabriela L B Costa, Karin Araujo Melo, José Pedro Cassemiro Micheleto, Vanessa Miranda Pereira Fausto, Laís Quintiliano Pedroza, Thiago Sotero Fragoso, Valfrido Leão de Melo Neto, Michelle Jacintha Cavalcante Oliveira
BackgroundPatients with a history of adverse childhood experiences (ACEs) have a higher incidence of developing autoimmune diseases such as systemic lupus erythematosus.ObjectiveThe objective is to associate the ACE with the clinical manifestations of SLE in adult women.MethodsThis is a cross-sectional observational analytical study in a sample of women diagnosed with SLE, whose data were collected
-
Comparison of the SLE Risk Probability Index (SLERPI) scale against the European League Against Rheumatism/American College of Rheumatology (ACR/EULAR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria Lupus (IF 2.6) Pub Date : 2024-03-06 Juan Pablo Castañeda-González, Silvia Alejandra Mogollón Hurtado, Adriana Rojas-Villarraga, Diana Guavita-Navarro, Laura Gallego-Cardona, Ana María Arredondo, Héctor Cubides, Claudia Ibáñez, Alejandro Escobar, Jairo Cajamarca-Barón
IntroductionTimely diagnosis and proper recognition of Systemic Lupus Erythematosus (SLE) is essential to establish early management in inpatients and outpatients. There are different classification scales to identify SLE, which include various clinical and serological aspects. In 2021, the SLE Risk Probability Index (SLERPI) was published, which focuses predominantly on the clinical characteristics
-
Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice Lupus (IF 2.6) Pub Date : 2024-03-06 Beatriz Frade-Sosa, Tarek Carlos Salman-Monte, Javier Narváez, Irene Peralta, Sebastian Sandoval, Berta Magallares, Sergi Heredia, Nuria Sapena, Anne Riveros-Frutos, Alejandro Olivé, Hector Corominas, Josefina Cortés-Hernández, José A Gómez-Puerta
BackgroundIn 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction
-
Skin erythematous migrant lesions consistent with histologically confirmed dermal arteriolar thrombosis connected to APS Lupus (IF 2.6) Pub Date : 2024-03-06 Silvia Suardi, Jacopo Croce, Chiara Colato, Paola Chiara Rizzo, Simonetta Friso, Francesca Pizzolo
Antiphospholipid syndrome (APS) is an acquired thrombophilic disorder related to the presence of antiphospholipid antibodies (LAC, anticardiolipin, anti Beta2-glycoprotein) known to cause venous and arterial thrombosis and recurrent pregnancy loss. Skin disorder is a frequent finding usually due to vascular thrombosis involving the dermal layer and can be either localized or widespread causing necrosis
-
Positive psychological capital, post-traumatic growth, social support, and quality of life in patients with systemic lupus erythematosus: A cross-sectional study Lupus (IF 2.6) Pub Date : 2024-03-05 Lyu Meng, Cui-Rong Gao, Hui-Cai Wang, Raxida Yasin, Rui-Jie Huang, Yu-Xin Zhao, Xiao-Hui Ma, Yuan-Yuan Wen
ObjectiveThis study aimed to investigate the correlation between positive psychological capital, post-traumatic growth, social support, and quality of life (QOL) in patients with systemic lupus erythematosus (SLE).MethodsA cross-sectional study was conducted at the First Affiliated Hospital of Xinjiang Medical University from October 2022 to May 2023. A sample of 330 hospitalized SLE patients was selected
-
Impact of preeclampsia on infant and maternal health among women with rheumatic diseases Lupus (IF 2.6) Pub Date : 2024-02-28 Megan E Milne, Megan EB Clowse, Congwen Zhao, Benjamin A Goldstein, Amanda M Eudy
ObjectivesWe sought to identify the impact of preeclampsia on infant and maternal health among women with rheumatic diseases.MethodsA retrospective single-center cohort study was conducted to describe pregnancy and infant outcomes among women with systemic lupus erythematosus (SLE) with and without preeclampsia as compared to women with other rheumatic diseases with and without preeclampsia.ResultsWe
-
Life expectancy and death pattern associated with systemic lupus erythematosus diagnosis in Brazil between 2000 and 2019 Lupus (IF 2.6) Pub Date : 2024-02-28 Edgard Torres dos Reis-Neto, Odirlei Andre Monticielo, Milena Daher, Flávia Lopes, Daniel Angrimani, Evandro Mendes Klumb
Objectivesto evaluate the main factors associated with mortality and determine the life expectancy of SLE patients between 2000 and 2019 years in Brazil.Methodsdeath data related to SLE available in the Brazilian Unified Health System (SUS) (DATASUS) were evaluated in all Brazilian states. Three groups of death causes potentially associated from SLE were evaluated: cardiovascular and kidney diseases
-
Genetically predicted circulating interleukin-18 levels are associated with risk of systemic lupus erythematosus and type 1 diabetes Lupus (IF 2.6) Pub Date : 2024-02-26 Wei-Zi Qin, Xu-Fan Wang, Rui Leng, Wen-Jing Xu, Fei-Fei Wang, Wei Zhao, Rui-Xue Leng
ObjectiveInterleukin-18 (IL-18) is a proinflammatory cytokine. This study aims to determine whether there is a causal relationship between circulating IL-18 concentrations and the risk of inflammatory and autoimmune diseases.MethodsWe collected significant single nucleotide polymorphisms (SNPs) associated with circulating IL-18 levels ( p < 5 × 10−8) as instrumental variables (IVs) from a genome-wide
-
Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of systemic lupus erythematosus in Canada: A scoping review Lupus (IF 2.6) Pub Date : 2024-02-10 Megan Thomas, Vanay Verma, Niloofar Gheshlaghi, John Esdaile, Antonio Avina-Zubieta, Cheryl Barnabe, Mark Harrison, Mary A De Vera
ObjectiveTo report participant characteristics relevant to identifying health inequities in systemic lupus erythematosus (SLE) randomized controlled trials conducted in Canada.MethodsWe conducted a scoping review by searching MEDLINE (Ovid) and Embase (1990 to June 2023), and CENTRAL (inception to June 2023). Eligible studies: used an RCT design; evaluated interventions (pharmacologic and non-pharmacologic)
-
Granulin in renal tubular epithelia is associated with interstitial inflammation and activates the TLR9-IFN-α pathway in lupus nephritis Lupus (IF 2.6) Pub Date : 2024-02-09 Lanting Huang, Yijun Dai, Zhenbo Geng, Hongyan He, Fuyuan Hong
ObjectiveThis study aimed to investigate the possible role of granulin (GRN) in activating the TLR9-IFN-α pathway in renal tubular epithelial cells (RTECs) and explore clues that RTECs regulate the micro-environment of inflammatory response in lupus nephritis (LN).MethodsRenal sections from 57 LN patients and 30 non-LN patients were sampled for histological study, and GRN overexpression RTECs were
-
Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus Lupus (IF 2.6) Pub Date : 2024-02-09 Nuntawan Piyaphanee, Sirirat Charuvanij, Sutheera Thepveera, Zheng Quan Toh, Paul V. Licciardi, Anirut Pattaragarn, Patimaporn Wongprompitak, Kobporn Boonnak, Chatkamol Pheerapanyawaranun, Kulkanya Chokephaibulkit
ObjectivesWe evaluated the immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus (adoSLE) receiving either high- or low-dose immunosuppressant (High-IS and Low-IS).MethodsPatients aged 12–18 years diagnosed with SLE were enrolled. High-IS was defined as >7.5 mg/day prednisolone or with other immunosuppressant, while Low-IS was defined as only ≤7.5 mg/day
-
Time to diagnosis in systemic lupus erythematosus: Associated factors and its impact on damage accrual and mortality. Data from a multi-ethnic, multinational Latin American lupus cohort Lupus (IF 2.6) Pub Date : 2024-02-09 Romina Nieto, Rosana Quintana, Ernesto Zavala-Flores, Rosa Serrano, Karen Roberts, Luis J Catoggio, Mercedes A García, Guillermo A Berbotto, Verónica Saurit, Eloisa Bonfa, Eduardo F Borba, Lilian T Lavras Costallat, Nilzio A Da Silva, Emilia I Sato, Joao C Tavares Brenol, Loreto Massardo, Oscar J Neira, Gloria Vázquez, Marlene Guibert Toledano, Virginia Pascual-Ramos, María J Sauza del Pozo, Leonor
BackgroundSystemic lupus erythematosus (SLE) often mimics symptoms of other diseases, and the interval between symptom onset and diagnosis may be long in some of these patients. Aims: To describe the characteristics associated with the time to SLE diagnosis and its impact on damage accrual and mortality in patients with SLE from a Latin American inception cohort.MethodsPatients were from a multi-ethnic
-
Non-invasive prediction of the chronic degree of lupus nephropathy based on ultrasound radiomics Lupus (IF 2.6) Pub Date : 2024-02-07 Chen Yin, Weihan Xiao, Xiaomin Hu, Xuebin Liu, Huaming Xian, Jun Su, Chaoxue Zhang, Xiachuan Qin
ObjectiveThrough machine learning (ML) analysis of the radiomics features of ultrasound extracted from patients with lupus nephritis (LN), this attempt was made to non-invasively predict the chronicity index (CI) of LN.MethodsA retrospective collection of 136 patients with LN who had renal biopsy was retrospectively collected, and the patients were randomly divided into training set and validation
-
Reduced miR-99a-3p levels in systemic lupus erythematosus may promote B cell proliferation via NCAPG and the PI3K/AKT signaling pathway Lupus (IF 2.6) Pub Date : 2024-02-06 Qing-huan Zhu, Ya-li Zhou, Meng Yang, Bin-bin Yang, Wen-ting Cao, Li-mei Yuan, Dan-qi Deng
BackgroundSystemic lupus erythematosus is an immunologically dysregulated disease characterized by the presence of multiple autoantibodies. In SLE, B lymphocytes contribute to the dysregulated production of autoantibodies and cytokines. Recently, we discovered that miR-99a-3p binds to both EIF4EBP1 and NCAPG mRNA and that lowering miR-99a-3p can promote B cell autophagy in SLE by increasing EIF4EBP1
-
Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series Lupus (IF 2.6) Pub Date : 2024-02-05 Nelson Luis Cahuapaza-Gutierrez
ObjectiveVaccination against SARS-CoV-2 reduced morbidity and mortality rates due to COVID-19 worldwide. However, several adverse effects have been documented and of great interest such as Systemic Lupus Erythematosus (SLE). The aim of the present study was to perform a systematic review of case reports and case series describing the development of SLE following COVID-19 against vaccination.MethodsCase
-
Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China Lupus (IF 2.6) Pub Date : 2024-02-05 Peng-Cheng Liu, Min Zhang, Jian-Bin Li, Yi-Lin Peng, Shu-Jiao Yu, Rui Wu
ObjectiveTo investigate characteristics associated with different COVID-19 outcomes of people with systemic lupus erythematosus (SLE) and COVID-19 during the second pandemic wave of COVID-19 in China.MethodsIn this retrospective study, people with SLE and COVID-19 who visited the First Affiliated Hospital of Nanchang University from December 2022 and February 2023 were subjected to this study. The
-
Juvenile neuropsychiatric systemic lupus erythematosus: A specific clinical phenotype and proposal of a probability score Lupus (IF 2.6) Pub Date : 2024-02-05 Mathilde Labouret, Vincent Trebossen, Alexandra Ntorkou, Sophie Bartoli, Mélodie Aubart, Stéphane Auvin, Brigitte Bader-Meunier, Véronique Baudouin, Olivier Corseri, Glory Dingulu, Camille Ducrocq, Cécile Dumaine, Monique Elmaleh, Nicole Fabien, Albert Faye, Isabelle Hau, Véronique Hentgen, Théresa Kwon, Ulrich Meinzer, Naim Ouldali, Cyrielle Parmentier, Marie Pouletty, Florence Renaldo, Isabelle Savioz
ObjectiveJuvenile systemic lupus erythematosus (j-SLE) is a rare chronic auto-immune disease involving several organs. Neuropsychiatric (NP) SLE (NPSLE) is frequent in j-SLE and associated with increased morbidity/mortality. Although NPSLE classification criteria exist, attributing NP features to j-SLE remains a major challenge. The study objective is to thoroughly describe j-NPSLE patients and assist
-
Bibliometric analysis of childhood-onset systemic lupus erythematosus from 2000 to 2022 Lupus (IF 2.6) Pub Date : 2024-02-02 Hao Yu, Xintong Xie, Guangliang Wei, Huidong Chen, Xue Zhang, Youxian He, Mengxiang Li, Chengsong He, Yue He, Jie Chen
BackgroundSystemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder. When SLE occurs in individuals under the age of 18, it is referred to as childhood-onset SLE (cSLE). Currently, there is a dearth of bibliometric research pertaining to cSLE.MethodRelevant studies in the field of cSLE from 2000 to 2022 were screened from the Web of Science Core Collection (WoSCC). CiteSpace
-
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE Lupus (IF 2.6) Pub Date : 2024-01-31 Junpeng Zhao, Liming Li, Xiwei Feng, Xinyu Fan, Huiqi Yin, Qianjin Lu
Immune checkpoints (ICs) play a pivotal role in orchestrating immune regulation, crucial for the maintenance of immune tolerance and prevention of autoimmune diseases. One noteworthy example among these immune regulators is T cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT). The TIGIT pathway’s inhibition or the absence of TIGIT has been linked to the
-
Network pharmacology and molecular docking to elucidate the common mechanism of hydroxychloroquine treatment in lupus nephritis and IgA nephropathy Lupus (IF 2.6) Pub Date : 2024-01-29 Yixuan Chen, Meiqi Lu, Mengshu Lin, Qing Gao
ObjectiveHydroxychloroquine (HCQ), characterized by a broad effect on immune regulation, has been widely used in the treatment of autoimmune glomerulonephritis such as lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN). The current research investigates whether HCQ plays a role in the treatment of LN and IgAN through common mechanisms since the pathogenesis of both LN and IgAN is closely
-
Systemic lupus erythematosus with chronic persistent intracranial hypertension: A case report Lupus (IF 2.6) Pub Date : 2024-01-29 Minchao Zou, Xinyu Jiang, Haifeng Chen, Fenghong Yuan
ObjectiveThe aim is to investigate the clinical characteristics of systemic lupus erythematosus with intracranial hypertension.MethodsThe clinical characteristics of one case of systemic lupus erythematosus with chronic persistent intracranial hypertension were analyzed, and related literature was reviewed by searching Medline and Wanfang databases.ResultsIntracranial hypertension in SLE patients may
-
Correlation between the changes of brain amplitude of low-frequency fluctuation and cognitive impairment in patients with neuropsychiatric lupus Lupus (IF 2.6) Pub Date : 2024-01-25 Yue Ma, Ning Tie, Sha Ni, Xueying Ma, Pengfei Qiao
PurposeTo explore the relationship between brain function changes and clinical serological indicators and behavioral cognitive assessment in patients with neuropsychiatric systemic lupus erythematosus (NPSLE), and understand the pathogenesis of NPSLE from the perspective of imaging.MethodsThe resting-state functional imaging data, clinical serological, and behavioral cognitive assessment scores of
-
Analysis of clinical, immunological characteristics, damage, and survival in 300 Turkish systemic lupus erythematosus patients Lupus (IF 2.6) Pub Date : 2024-01-23 Senem Tekeoglu, Duygu Temiz Karadag, Ozlem Ozdemir Isik, Ayten Yazici, Ayse Cefle
ObjectiveThis retrospective study aimed to conduct a comprehensive analysis of Turkish Systemic Lupus Erythematosus (SLE) patients of Caucasian ethnicity, focusing on their clinical, immunological, and therapeutic characteristics, damage accural and mortality.Patients and MethodsWe carried out a retrospective assessment of 300 SLE patients diagnosed between 2001 and 2017 at Kocaeli University Rheumatology
-
A 12-month follow-up study of patients with systemic lupus erythematosus after immunization against SARS-CoV-2 Lupus (IF 2.6) Pub Date : 2024-01-19 Ernesto Zavala-Flores, Jannin Salcedo-Matienzo, Roberto Huamanchumo-Guzman, Alfredo Berrocal-Kasay, Graciela S Alarcón
ObjectiveTo identify all post-BNT162b2 vaccination (BioNTech and Pfizer) events during the ensuing 12 months in patients with systemic lupus erythematosus (SLE) from the Immuno-Rheumatology Department at Cayetano Heredia Hospital’s cohort, Lima, Perú.MethodsA 12-month follow-up study was conducted from the first dose of immunization with the BNT162b2 vaccine, which was given between May and June 2021
-
The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus Lupus (IF 2.6) Pub Date : 2024-01-19 Amanda M Eudy, Megan EB Clowse, Amy Corneli, Kevin McKenna, David S Pisetsky, Mithu Maheswaranathan, Dana Burshell, Jayanth Doss, Kai Sun, Rebecca E Sadun, Lisa G Criscione-Schreiber, Jennifer L Rogers
ObjectiveIn the new Type 1 & 2 model for systemic lupus erythematosus (SLE), Type 1 SLE represents classic inflammatory manifestations, such as arthritis, while Type 2 SLE encompasses symptoms such as pain and fatigue where the relationship to inflammation is less clear. The objective of this study was to interview individuals living with SLE to determine the content and face validity of the Type 1
-
Neutrophilic dermatoses as a manifestation of a systemic lupus erythematosus flare Lupus (IF 2.6) Pub Date : 2024-01-18 Yingxue Wang, Eugenia Chen, Priyanka Iyer
Neutrophilic dermatoses (NDs) refer to a group of cutaneous conditions histologically characterized by the dense accumulation of neutrophils in the skin in the absence of infection. NDs have been associated with underlying autoimmune connective tissue disorders (CTDs) such as systemic lupus erythematosus (SLE), Sjogren’s syndrome, and dermatomyositis. We describe a case of neutrophilic dermatoses as
-
Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis Lupus (IF 2.6) Pub Date : 2024-01-17 Mai Kawazoe, Toshihiro Nanki
ObjectivesTo evaluate the renal response to mycophenolate mofetil (MMF) as maintenance therapy for lupus nephritis (LN) in Japanese patients, we compared the efficacy of MMF and the sequential use of monthly intravenous cyclophosphamide (IVCY) followed by tacrolimus (TAC).MethodsWe examined 14 patients with LN who were treated with continuous MMF as induction and maintenance therapies (MMF group) and
-
Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis Lupus (IF 2.6) Pub Date : 2024-01-16 Sihao Qin, Xueyao Wang, Jiahui Wang, Hao Wu
Background: Increasing studies in the last decade have led to the widespread understanding that C4d, a split product of complement component 4 (C4), is a potential biomarker for systemic lupus erythematosus (SLE) and lupus nephritis (LN).Purpose: The aim of this review is to summarize the highlights of studies investigating the use of C4d as a biomarker for diagnosing and monitoring SLE and LN patients
-
Rhupus syndrome in children: A multi-center retrospective cohort study and literature review Lupus (IF 2.6) Pub Date : 2024-01-16 Seher Sener, Ezgi Deniz Batu, Sezgin Sahin, Deniz Gezgin Yildirim, Miray Kisla Ekinci, Hakan Kisaoglu, Yasin Karali, Selcan Demir, Ummusen Kaya Akca, Aybuke Gunalp, Seyma Turkmen, Gulsah Kavrul Kayaalp, Ceyda Arslanoglu, Ruya Torun, Ozge Basaran, Aysenur Pac Kisaarslan, Betul Sozeri, Nuray Aktay Ayaz, Sevcan Azime Bakkaloglu, Sara Sebnem Kilic, Mukaddes Kalyoncu, Yelda Bilginer, Erbil Unsal, Ozgur
ObjectiveIn this study, we aimed to evaluate the characteristics of pediatric rhupus patients including all the related series in the literature.MethodsThirty pediatric patients with rhupus syndrome from 12 different centers in Turkey were included in this study. The literature was also reviewed for pediatric patients with rhupus syndrome.ResultsThe most prominent phenotype of these 30 patients was
-
The potential causal association between systemic lupus erythematosus and endocrine and metabolic disorders in the East Asian population: A bidirectional two-sample Mendelian randomization study Lupus (IF 2.6) Pub Date : 2024-01-12 Tingliang Wang, Yun Zhang, Xuelan Chen, Zhenxing Huang, Xinghuan Liang, Yingfen Qin, Zuojie Luo
ObjectivesObservational studies indicate a significant correlation between systemic lupus erythematosus (SLE) and endocrine and metabolic disorders, but the causal association between SLE and endocrine and metabolic disorders remains unclear due to the reverse causality and confounding biases commonly presented in conventional observational research. This study endeavors to uncover the causal association
-
Effect of classroom-based physical activity on teaching quality of systemic lupus erythematosus for medical undergraduates Lupus (IF 2.6) Pub Date : 2024-01-11 Yong Chen, Mang He, Shidan Tian, Yan Jiang, Yongqiao Zhang, Yupei Lin, Zhouxiong Xing, Kutty Selva Nandakumar, Mei Tian
ObjectiveTo explore the influence of classroom-based physical activity (CB-PA) on the teaching quality of systemic lupus erythematosus (SLE) for medical undergraduates.MethodsStudents from 8 classes participating in the clinical medicine program of the affiliated hospital of Zunyi Medical University were divided into two groups. Four classes received regular teaching on the SLE chapter as the control
-
Lupus nephritis and socioeconomic status: Findings from the Southern California lupus registry Lupus (IF 2.6) Pub Date : 2024-01-11 Vaneet K. Sandhu, Arezoo Haghshenas, Phildrich Teh, Emily He, Abigail Benitez, Lorena M Salto, Karina Torralba
ObjectiveLupus nephritis (LN) is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Despite multiple studies addressing healthcare disparities, disparate outcomes in LN persist. We investigate herein the association between socioeconomic status (SES) and LN as well as the association between SES, SLE disease activity index (SLEDAI), and treatment response.MethodsPatients
-
Analysis of 5-year hospitalization data of patients with systemic lupus erythematosus: Damage is a risk factor for frequent and longer stays Lupus (IF 2.6) Pub Date : 2024-01-10 Çiğdem Çetin, Melodi Gizem Can, Sinem Öztaşkın, Yasemin Yalçınkaya, Ahmet Gül, Murat İnanç, Bahar Artım Esen
ObjectiveThe annual hospitalization rate of patients with systemic lupus erythematosus (SLE) is approximately 10%, and hospitalizations are responsible for most of the healthcare expenses. Herein, we analyzed 5-year hospitalization data of SLE patients and determined factors leading to hospitalization.MethodsClinical, laboratory, and hospitalization data of SLE patients admitted to our rheumatology
-
Systemic lupus erythematosus is associated with increased risk of mortality and acute kidney injury in patients with COVID-19 hospitalization: Insights from a National Inpatient Sample analysis Lupus (IF 2.6) Pub Date : 2024-01-09 Anum Akhlaq, Sameen Aamer, Khawaja Muthammir Hasan, Taimur Sohail Muzammil, Amir Humza Sohail, Mohammed A Quazi, Muhammad Salman Khan, Abu Baker Sheikh
IntroductionThe COVID-19 pandemic has significantly impacted global health, especially for patients with chronic diseases that may compromise the immune system. This study investigates the association between systemic lupus erythematosus (SLE) and COVID-19 outcomes.MethodsData from the National Inpatient Sample (NIS) were analyzed to create a retrospective cohort of COVID-19 hospitalizations, comparing
-
The effect of respiratory muscle training on respiratory muscle strength, diaphragm thickness/mobility, and exercise capacity in patients with systemic lupus erythematosus and associated shrinking lung syndrome Lupus (IF 2.6) Pub Date : 2024-01-09 Fulden Sari, Deran Oskay, Abdurrahman Tufan
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that can impact any organ in the body. The pathophysiology of shrinking lung syndrome (SLS), a rare pulmonary complication of SLE, remains unknown. The objective of the current case series was to investigate the effects of inspiratory muscle training (IMT) on diaphragm thickness/mobility, respiratory muscle strength, peripheral muscle
-
Clinical algorithm model based on cfDNA to predict SLE disease activity Lupus (IF 2.6) Pub Date : 2024-01-06 Fang Wang, Yi-jing Liu, Hai-Bing Miao, Zhen Chen
BackgroundCirculating cell-free DNA (cfDNA) has been widely used as a new liquid-biopsy marker. Dysregulation of cfDNA has been found in patients with systemic lupus erythematosus (SLE). However, the detailed association between cfDNA and SLE has not been thoroughly studied.MethodsPlasma samples were collected from 88 patients with active SLE and 39 patients with inactive SLE. The cfDNA concentration
-
Right ventricular-pulmonary arterial coupling ratio derived from 3-dimensional echocardiography predicts outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension patients Lupus (IF 2.6) Pub Date : 2024-01-06 Wei-Fang Lan, Yan Deng, Ping Dai, Dan-dan Wu, Jie Hu, Juan Liao, Hui Meng
BackgroundSystemic lupus erythematosus (SLE) is a complex autoimmune connective tissue disease (CTD) that is an important cause of devastating pulmonary arterial hypertension (PAH), and persistent progression of PAH can lead to right heart failure, predicting a poor prognosis for SLE patients. Right ventricular-pulmonary arterial (RV-PA) coupling with echocardiography has been demonstrated to be a
-
Integrating spiritual disposition intervention into behavioral medicine: A case report on systemic lupus erythematosus from India Lupus (IF 2.6) Pub Date : 2024-01-03 Ishanpreet Kaur Toor, Kritika Rastogi, Sajal Ajmani
Background: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory systemic autoimmune disease. The disease manifests as the body’s immune cells start attacking healthy connective tissue, which affects the skin, kidneys, blood vessels, brain, and other vital organs. As with any other chronic illness, the disease has psychological implications.Purpose: Literature suggests patients with SLE experience
-
A qualitative study of facilitators of medication adherence in systemic lupus erythematosus: Perspectives from rheumatology providers/staff and patients Lupus (IF 2.6) Pub Date : 2024-01-02 Shannon Herndon, Amy Corneli, Carrie Dombeck, Teresa Swezey, Megan EB Clowse, Jennifer L Rogers, Lisa G Criscione-Schreiber, Rebecca E Sadun, Jayanth Doss, Amanda M Eudy, Hayden B Bosworth, Kai Sun
ObjectiveSystemic lupus erythematosus (SLE) disproportionately affects patients from racial and ethnic minority groups. Medication adherence is lower among these patient populations, and nonadherence is associated with worse health outcomes. We aimed to identify factors that enable adherence to immunosuppressive medications among patients with SLE from racial and ethnic minority groups.MethodsUsing
-
COVID vaccine–induced lupus nephritis: Case report and review of the literature Lupus (IF 2.6) Pub Date : 2024-01-02 Antonio Salas, Ayotola Fatola, Rebecca Krimins, Ihab R Kamel, Duvuru Geetha, Derek Fine, Manny Monroy-Trujillo, Avi Rosenberg, Lois Arend, Homa Timlin
Vaccines offer an effective strategy to prevent infectious diseases with minimal adverse effects. On rare occasions, vaccination can disrupt the immune response leading to induction of autoimmune diseases. We describe a case of new-onset lupus nephritis following COVID-19 vaccination with the first dose of the Pfizer vaccine. Her symptoms and lab values improved with steroids, hydroxychloroquine, and
-
Cardiovascular disease risk perceptions and influencing factors among Chinese systemic lupus erythematosus patients. Lupus (IF 2.6) Pub Date : 2023-12-01 Yuge Zhang,Juan Yu,Wenjing Zhao,Min Zhang,Qing Bao,Hailing Zhang
BACKGROUND Systemic Lupus Erythematosus patients (SLE) are at a higher risk of cardiovascular events than the general population. This study aimed to investigate the risk perception of cardiovascular disease (CVD) and to analyze its influence factors among Chinese SLE patients. METHODS This was a cross-sectional study. Convenience sampling was used to select 201 patients with SLE who had attended the
-
Referral and evaluation for kidney transplantation among patients with lupus nephritis-related end-stage kidney disease. Lupus (IF 2.6) Pub Date : 2023-11-29 Laura McPherson,Laura C Plantinga,Penelope P Howards,Michael Kramer,Stephen O Pastan,Rachel E Patzer
OBJECTIVE For the majority of patients with lupus nephritis-related end-stage kidney disease (LN-ESKD), kidney transplant is associated with better outcomes than dialysis. Access to kidney transplant requires an initial referral to a transplant center and medical evaluation prior to waitlisting. The study's objective was to examine access to these early steps in the kidney transplant process among
-
Lymphoid interstitial pneumonia in a patient with systemic lupus erythematosus: Case report and literature review. Lupus (IF 2.6) Pub Date : 2023-11-29 Laura Dans Vilán,Raquel Ríos Fernández,Sergio Fernández Ontiveros,Miguel Suárez Robles,Mercedes Caba Molina,Marta García Morales,Francisco Javier De la Hera,Norberto Ortego Centeno,Jose Luis Callejas Rubio
Lymphoid interstitial pneumonia (LIP) is a rare form of interstitial pulmonary disease, which has been described in association with a wide range of autoimmune disorders. Although the association of this entity with Sjogren's syndrome is well known, only a few cases are reported in relation to systemic lupus erythematosus (SLE). The aim of this paper is to review the cases reported in literature to
-
-
Letter re: Lupus erythematosus masquerading as acneiform lesions: two cases and review of the literature. Lupus (IF 2.6) Pub Date : 2023-11-24 Victor García-Rodríguez,J Arandes-Marcocci,M Iglesias-Sancho,D Marín-Piñero,C Barrabés-Torrella,M T Fernández-Figueras,M Salleras-Redonnet
-
Development and psychometric properties of the Reproductive Health Assessment in Systemic Lupus Erythematosus: Mixed-Methods study. Lupus (IF 2.6) Pub Date : 2023-11-21 Zahra Behboodi Moghadam,Armin Zareiyan,Seyedeh Tahereh Faezi,Elham Rezaei
OBJECTIVES Systemic lupus erythematosus (SLE) with a high morbidity rate (7% in general and 325/100.000 in reproductive period) was known as "the mother of autoimmune diseases." But healthcare providers hadn't reliable scales to measure the effectiveness of interventions to improve reproductive health. Women with systemic lupus erythematosus (SLE) express concern about a significant gap in their reproductive
-
The impact of pregnancy planning and medical readiness on reproductive outcomes in women with systemic lupus erythematosus. Lupus (IF 2.6) Pub Date : 2023-11-15 Catherine A Sims,Amanda M Eudy,Jayanth Doss,Jennifer L Rogers,Rebecca E Sadun,Lisa Criscione-Schreiber,Kai Sun,Megan Eb Clowse
Women with systemic lupus erythematosus (SLE) who get pregnant while SLE is active or while on teratogens have higher risk of poor pregnancy outcomes. The American College of Rheumatology (ACR) Reproductive Health Guidelines recommend women conceive when SLE is well controlled and treated with pregnancy-compatible medications. The Healthy Outcomes in Pregnancy with SLE Through Education of Providers
-
Epidemiology and outcomes of emergency department visits in systemic lupus erythematosus: Insights from the nationwide emergency department sample (NEDS). Lupus (IF 2.6) Pub Date : 2023-11-14 Rashmi Dhital,Ashbina Pokharel,Ioannis Karageorgiou,Dilli R Poudel,Monica Guma,Kenneth Kalunian
BACKGROUND Systemic lupus erythematosus (SLE) patients are prone to frequent emergency department (ED) visits. This study explores the epidemiology and outcomes of ED visits by patients with SLE utilizing the Nationwide Emergency Department Sample (NEDS). METHODS Using NEDS (2019), SLE ED visits identified using ICD-10 codes (M32. xx) were compared with non-SLE ED visits in terms of demographic and
-
Burden of lupus activity on health care resources utilization in Buenos Aires, Argentina. Lupus (IF 2.6) Pub Date : 2023-11-13 Rodolfo Nicolas Alvarado,Gelsomina Alle,Mayra Alejandra Tobar-Jaramillo,Luis Carlos Palomino,Agustín Gabriel Cáceres,Javier Eduardo Rosa,Gerardo Machnicki,Federico Zazzetti,Enrique Soriano,Marina Scolnik
OBJECTIVE The aim is to analyze health care resource utilization (HCRU) of patients with lupus (SLE) from a health management organization (HMO) in Buenos Aires, Argentina, compared with matched controls and comparing periods of flare, low disease activity, and remission. METHODS This is a retrospective observational study including all SLE incident cases (ACR 1997/SLICC 2012 criteria) between 2000
-
Polyneuritis cranialis as a unique initial presentation of juvenile systemic lupus erythematosus: Case report. Lupus (IF 2.6) Pub Date : 2023-11-09 Hoda Tomoum,Rasha El-Owaidy,Abeer El-Zohiery
Cranial neuropathy is a rare presentation in juvenile (j) SLE and being multiple is even rarer. We describe here an adolescent girl presenting with polyneuritis cranialis (PNC) as an initial presentation of SLE which had not been reported before in literature. She presented with symptoms suggestive of bilateral abducent and hypoglossal neuropathy with nerve conduction studies showing partial axonal
-
Active lupus in Argentina: Results of a multicenter and national registry. Lupus (IF 2.6) Pub Date : 2023-11-08 Rosana M Quintana,Mercedes García,Lucila Garcia,Carla Gobbi,Paula Alba,Verónica Bellomio,Susana Roverano,Analia Patricia Alvarez,Cesar Enrique Graf,Cecilia Pisoni,Alberto Spindler,Catalina Gomez,Heber Matias Figueredo,Silvia Papasidero,Raul Paniego,Maria Celina de la Vega,Emma Civit,Luciana Gonzalez Lucero,Maria Victoria Martire,Rodrigo Aguila Maldonado,Sergio Gordon,Marina Micelli,Romina Nieto,Gretel
OBJECTIVE To evaluate the association between patients' characteristics and disease activity in an Argentine lupus registry. METHODS Cross-sectional study. Disease activity was stratified into: Remission off-treatment: SLEDAI = 0, without prednisone and immunosuppressive drugs. Low disease activity Toronto Cohort (LDA-TC): SLEDAI ≤2, without prednisone or immunosuppressive drugs. Modified lupus low
-
Efficacy of the COVID-19 vaccine in pediatric systemic lupus erythematosus patients. Lupus (IF 2.6) Pub Date : 2023-11-06 Yi Shi,Sangeeta Sule,Catherine Park,Sun-Young Ahn
-
COVID-19 and SLE: Infection and autoimmunity at its best. Lupus (IF 2.6) Pub Date : 2023-11-05 Naim Mahroum,Abdulrahman Elsalti,Mehmet Fatih Ozkan,Yehuda Shoenfeld
If one had any doubts before the pandemic regarding the correlation between infections and autoimmunity, COVID-19 left us fascinated on the strong bond between the two entities. The immune and autoimmune reactions seen in patients infected with SARS-CoV-2 have served as a base for this assumption. Later on, the use of immunosuppressants such as systemic glucocorticoids, among other biological agents
-
Systemic Lupus Erythematosus and the Ratio of Omega-3 to Omega-6 Fatty Acids Consumption among Women in the Adventist Health Study-2. Lupus (IF 2.6) Pub Date : 2023-11-05 Jisoo Oh,Keiji Oda,Marissa Brash,W Lawrence Beeson,Joan Sabaté,Gary E Fraser,Synnove F Knutsen
OBJECTIVE To assess the associations of omega-3 and omega-6 fatty acids consumption, and the ratio between the two, with self-reported doctor told Systemic Lupus Erythematosus (SLE) diagnosis. Further, to assess whether initiation of omega-3 supplements intake was related to time/year of SLE diagnosis. METHODS Data from 42,398 women in the Adventist Health Study-2 cohort were used for this cross-sectional